<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="825">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01928472</url>
  </required_header>
  <id_info>
    <org_study_id>V131_01</org_study_id>
    <nct_id>NCT01928472</nct_id>
  </id_info>
  <brief_title>Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years</brief_title>
  <official_title>Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to &lt;65 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults
      between the ages of 18 years and 65 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43)</measure>
    <time_frame>Day 1 and 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was measured by Hemagglutination Inhibition (HI) assay and summarized through the geometric mean titers (GMTs) at baseline (day 1) and three weeks after the second (day 43) vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 43)</measure>
    <time_frame>Day 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after second (day 43) vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</measure>
    <time_frame>Day 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after second (day 43) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages Of Subjects With an HI Titers ≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</measure>
    <time_frame>Day 1 and 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after second (Day 43) vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</measure>
    <time_frame>Day 1 to Day 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety was assessed as the number of subjects who reported any AEs, and at least possibly related AEs are collected from day 1 to day 43 following vaccination with adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</measure>
    <time_frame>Day 1 to Day 366.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of subjects reporting unsolicited adverse events after receiving adjuvanted and unadjuvanted formulations of H7N9c vaccine was reported. Safety was assessed as the number of subjects who reported SAEs, at least possibly related SAEs, new onset of chronic diseases (NOCDs), medically attended AEs, AEs of Special Interest (AESIs), AEs leading to withdrawal from the study were collected from day 1 to day 366 following vaccination with adjuvanted and unadjuvanted formulations of H7N9 vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</measure>
    <time_frame>Day 1 through Day 7 after each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 to day 7 of vaccination of adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers Of Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Monovalent Vaccine, HI Assay (Day 22)</measure>
    <time_frame>Day 1 and 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity was measured by HI assay and summarized through the GMTs at baseline (day 1) and three weeks after the first (day 22) vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 22)</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after first (day 22) vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after first (day 22) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With an HI Titers≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</measure>
    <time_frame>Day 1 and 22.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after first (Day 22) vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</measure>
    <time_frame>Day 183 and 366.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity was measured as GMTs in subjects as persistence at six months (day 183) and one year (day 366) after the first vaccination as measured by Hemagglutination Inhibition (HI) Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratios at Six Months and One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</measure>
    <time_frame>Day 183 and 366</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs six months (day 183) and one year (day 366) after the first vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects Achieving Seroconversion at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</measure>
    <time_frame>Day 183 and 366</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with HI seroconversion was measured as HI titer persistence at six months (day 183) and one year (day 366) after the first vaccination.
Seroconversion is defined as postvaccination HI titer&gt;40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum four-fold increase in titer for subjects with baseline titer&gt;1:10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages Of Subjects With an HI Titers ≥1:40 at Six Months and at One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</measure>
    <time_frame>Day 183 and 366</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentages of subjects who achieved HI titers≥1:40 was measured at six months (day 183) and one year (day 366) after the first vaccination of a cell-culture derived H7N9 vaccine.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>H7N9 Influenza</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7N9c low dose with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7N9c medium dose with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7N9c high dose with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H7N9c high dose without adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9c low dose with adjuvant</intervention_name>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9c medium dose with adjuvant</intervention_name>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9c high dose with adjuvant</intervention_name>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H7N9c high dose without adjuvant</intervention_name>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult subject ages 18-64 years.

          2. Individuals willing to provide written informed consent

          3. Individuals in good health.

          4. Individuals who can comply with study procedures and follow-up.

        Exclusion Criteria:

          1. Individuals with history of cognitive or behavioral impairment or psychiatric
             disease,

          2. Individuals unable to understand and follow study procedures,

          3. History of significant illness,

          4. History of chronic medical condition or progressive disease,

          5. Allergy to any vaccine component or adverse event related to a vaccine component,

          6. Impairment/alteration of the immune system,

          7. Presence of progressive or severe neurological disorder,

          8. Pregnant or breast-feeding,

          9. Female of Child-bearing potential unwilling to use acceptable method of birth
             control,

         10. Presence of medically significant cancer,

         11. Receipt of investigational product within 30 day prior to entry into the study,

         12. History of previous or suspected illness from avian flu caused by H7N9 virus,

         13. History of H7 vaccination,

         14. Body temperature of greater than or equal to 38.0°C (100.4◦F) and/or acute illness
             within 3 days of intended study vaccination,

         15. Receipt of any flu vaccination 2 weeks before study entry or 4 weeks after study
             vaccination,

         16. Receipt of any vaccination 2 weeks before study entry or 4 weeks after study
             vaccination,

         17. History of drug or alcohol abuse within the past 2 years,

         18. Body Mass Index (BMI) greater than or equal to 35kg/m2,

         19. Individuals conducting the study or their immediate family members.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 04: Accelovance</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01: Accelovance</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02: Accelovance</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03: Accelovance</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05: Janet Lewis</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06: Janet Lewis</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 5, 2015</lastchanged_date>
  <firstreceived_date>August 21, 2013</firstreceived_date>
  <firstreceived_results_date>May 5, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza, H7N9, Vaccine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza in Birds</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 6 centers in United States.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="P3">
          <title>High Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="P4">
          <title>High Dose + No Adj</title>
          <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="96"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
        </group>
        <group group_id="B2">
          <title>Medium Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="B3">
          <title>High Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="B4">
          <title>High Dose + No Adj</title>
          <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="B5">
          <title>TOTAL</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="98"/>
                <measurement group_id="B2" value="104"/>
                <measurement group_id="B3" value="98"/>
                <measurement group_id="B4" value="102"/>
                <measurement group_id="B5" value="402"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.3" spread="13.1"/>
                <measurement group_id="B2" value="40.3" spread="12.5"/>
                <measurement group_id="B3" value="42.6" spread="13.1"/>
                <measurement group_id="B4" value="43.4" spread="12.9"/>
                <measurement group_id="B5" value="41.2" spread="13.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="48"/>
                <measurement group_id="B4" value="53"/>
                <measurement group_id="B5" value="218"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="50"/>
                <measurement group_id="B4" value="49"/>
                <measurement group_id="B5" value="184"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43)</title>
        <description>Immunogenicity was measured by Hemagglutination Inhibition (HI) assay and summarized through the geometric mean titers (GMTs) at baseline (day 1) and three weeks after the second (day 43) vaccination</description>
        <time_frame>Day 1 and 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on Full Analysis Set – Subjects who received at least one study vaccination and provided immunogenicity at day 43 (FAS-Day 43).</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers Of Subjects After Each Vaccination Of a Cell-Culture Derived H7N9c Monovalent Vaccine, Hemagglutination Inhibition Assay (Day 43)</title>
            <description>Immunogenicity was measured by Hemagglutination Inhibition (HI) assay and summarized through the geometric mean titers (GMTs) at baseline (day 1) and three weeks after the second (day 43) vaccination</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O2" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O3" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O4" value="5.05" lower_limit="5" upper_limit="5.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 43 (N=94,103,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12" lower_limit="9.75" upper_limit="15"/>
                  <measurement group_id="O2" value="19" lower_limit="15" upper_limit="23"/>
                  <measurement group_id="O3" value="26" lower_limit="21" upper_limit="32"/>
                  <measurement group_id="O4" value="5.75" lower_limit="4.67" upper_limit="7.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 43)</title>
        <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after second (day 43) vaccination.</description>
        <time_frame>Day 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 43</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 43)</title>
            <description>Geometric mean ratio (GMR) of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after second (day 43) vaccination.</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.42" lower_limit="1.95" upper_limit="3"/>
                  <measurement group_id="O2" value="3.7" lower_limit="3.02" upper_limit="4.55"/>
                  <measurement group_id="O3" value="5.2" lower_limit="4.21" upper_limit="6.43"/>
                  <measurement group_id="O4" value="1.14" lower_limit="0.93" upper_limit="1.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</title>
        <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after second (day 43) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
        <time_frame>Day 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 43</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="94"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</title>
            <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after second (day 43) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26" lower_limit="17" upper_limit="36"/>
                  <measurement group_id="O2" value="44" lower_limit="34" upper_limit="54"/>
                  <measurement group_id="O3" value="52" lower_limit="41" upper_limit="62"/>
                  <measurement group_id="O4" value="3" lower_limit="1" upper_limit="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages Of Subjects With an HI Titers ≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</title>
        <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after second (Day 43) vaccination.</description>
        <time_frame>Day 1 and 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 43.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects With an HI Titers ≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 43)</title>
            <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after second (Day 43) vaccination.</description>
            <units>Percentages of subejcts</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 43 (N=94,103,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26" lower_limit="17" upper_limit="36"/>
                  <measurement group_id="O2" value="44" lower_limit="34" upper_limit="54"/>
                  <measurement group_id="O3" value="52" lower_limit="41" upper_limit="62"/>
                  <measurement group_id="O4" value="3" lower_limit="1" upper_limit="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers Of Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Monovalent Vaccine, HI Assay (Day 22)</title>
        <description>Immunogenicity was measured by HI assay and summarized through the GMTs at baseline (day 1) and three weeks after the first (day 22) vaccination.</description>
        <time_frame>Day 1 and 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 22</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers Of Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Monovalent Vaccine, HI Assay (Day 22)</title>
            <description>Immunogenicity was measured by HI assay and summarized through the GMTs at baseline (day 1) and three weeks after the first (day 22) vaccination.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O2" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O3" value="5" lower_limit="4.95" upper_limit="5.05"/>
                  <measurement group_id="O4" value="5.05" lower_limit="5" upper_limit="5.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22 (N=96,103,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.07" lower_limit="4.95" upper_limit="5.2"/>
                  <measurement group_id="O2" value="5" lower_limit="4.88" upper_limit="5.12"/>
                  <measurement group_id="O3" value="5" lower_limit="4.88" upper_limit="5.13"/>
                  <measurement group_id="O4" value="5.1" lower_limit="4.98" upper_limit="5.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 22)</title>
        <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after first (day 22) vaccination.</description>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 22</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratios In Subjects After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Day 22)</title>
            <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs three weeks after first (day 22) vaccination.</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.01" lower_limit="1" upper_limit="1.03"/>
                  <measurement group_id="O2" value="1" lower_limit="0.98" upper_limit="1.02"/>
                  <measurement group_id="O3" value="1" lower_limit="0.98" upper_limit="1.02"/>
                  <measurement group_id="O4" value="1.01" lower_limit="0.99" upper_limit="1.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</title>
        <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after first (day 22) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
        <time_frame>Day 22</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 22</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects Achieving Seroconversion After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</title>
            <description>Percentage of subjects achieving HI seroconversion in HI titer was measured three weeks after first (day 22) vaccination.
Seroconversion is defined as postvaccination HI titer&gt; 40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum 4-fold increase in titer for subjects with baseline titer &gt;1:10.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With an HI Titers≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</title>
        <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after first (Day 22) vaccination.</description>
        <time_frame>Day 1 and 22.</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 22</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects With an HI Titers≥1:40 After Each Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Day 22)</title>
            <description>Percentage of subjects who achieved HI titers≥1:40 was measured at baseline (day 1) and three weeks after first (Day 22) vaccination.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</title>
        <description>The immunogenicity was measured as GMTs in subjects as persistence at six months (day 183) and one year (day 366) after the first vaccination as measured by Hemagglutination Inhibition (HI) Assay.</description>
        <time_frame>Day 183 and 366.</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 183 and FAS-Day 366</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="101"/>
                  <measurement group_id="O3" value="94"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</title>
            <description>The immunogenicity was measured as GMTs in subjects as persistence at six months (day 183) and one year (day 366) after the first vaccination as measured by Hemagglutination Inhibition (HI) Assay.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 183</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.17" lower_limit="4.84" upper_limit="5.52"/>
                  <measurement group_id="O2" value="5.43" lower_limit="5.1" upper_limit="5.78"/>
                  <measurement group_id="O3" value="5.99" lower_limit="5.61" upper_limit="6.39"/>
                  <measurement group_id="O4" value="5.16" lower_limit="4.84" upper_limit="5.49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 366 (N=90,96,91,100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5" lower_limit="4.78" upper_limit="5.23"/>
                  <measurement group_id="O2" value="5.14" lower_limit="4.92" upper_limit="5.37"/>
                  <measurement group_id="O3" value="5.14" lower_limit="4.92" upper_limit="5.38"/>
                  <measurement group_id="O4" value="5.16" lower_limit="4.94" upper_limit="5.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratios at Six Months and One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</title>
        <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs six months (day 183) and one year (day 366) after the first vaccination.</description>
        <time_frame>Day 183 and 366</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 183 and FAS-Day 366</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="101"/>
                  <measurement group_id="O3" value="94"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Ratios at Six Months and One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine, HI Assay (Persistence)</title>
            <description>GMR of subjects was calculated as the ratio of postvaccination to prevaccination HI GMTs six months (day 183) and one year (day 366) after the first vaccination.</description>
            <units>Ratio</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 183/Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.03" lower_limit="0.97" upper_limit="1.1"/>
                  <measurement group_id="O2" value="1.09" lower_limit="1.02" upper_limit="1.15"/>
                  <measurement group_id="O3" value="1.2" lower_limit="1.13" upper_limit="1.27"/>
                  <measurement group_id="O4" value="1.02" lower_limit="0.96" upper_limit="1.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 366/Day 1 (N=90,96,91,100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" lower_limit="0.96" upper_limit="1.04"/>
                  <measurement group_id="O2" value="1.03" lower_limit="0.99" upper_limit="1.07"/>
                  <measurement group_id="O3" value="1.03" lower_limit="0.99" upper_limit="1.07"/>
                  <measurement group_id="O4" value="1.02" lower_limit="0.98" upper_limit="1.06"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects Achieving Seroconversion at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</title>
        <description>Percentage of subjects with HI seroconversion was measured as HI titer persistence at six months (day 183) and one year (day 366) after the first vaccination.
Seroconversion is defined as postvaccination HI titer&gt;40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum four-fold increase in titer for subjects with baseline titer&gt;1:10.</description>
        <time_frame>Day 183 and 366</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 183 and FAS-Day 366</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="101"/>
                  <measurement group_id="O3" value="94"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects Achieving Seroconversion at Six Months and One Year After Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</title>
            <description>Percentage of subjects with HI seroconversion was measured as HI titer persistence at six months (day 183) and one year (day 366) after the first vaccination.
Seroconversion is defined as postvaccination HI titer&gt;40 for subjects with baseline (day 1); HI titer &lt;1:10 or a minimum four-fold increase in titer for subjects with baseline titer&gt;1:10.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 183</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="1" lower_limit="0.025" upper_limit="5"/>
                  <measurement group_id="O3" value="1" lower_limit="0.027" upper_limit="6"/>
                  <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 366 (N=90,96,91,100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="1" lower_limit="0.026" upper_limit="6"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages Of Subjects With an HI Titers ≥1:40 at Six Months and at One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</title>
        <description>Percentages of subjects who achieved HI titers≥1:40 was measured at six months (day 183) and one year (day 366) after the first vaccination of a cell-culture derived H7N9 vaccine.</description>
        <time_frame>Day 183 and 366</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS-Day 183 and FAS-Day 366</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="101"/>
                  <measurement group_id="O3" value="94"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages Of Subjects With an HI Titers ≥1:40 at Six Months and at One Year After the First Vaccination Of A Cell-Culture Derived H7N9c Vaccine (Persistence)</title>
            <description>Percentages of subjects who achieved HI titers≥1:40 was measured at six months (day 183) and one year (day 366) after the first vaccination of a cell-culture derived H7N9 vaccine.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 183</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="1" lower_limit="0.025" upper_limit="5"/>
                  <measurement group_id="O3" value="1" lower_limit="0.027" upper_limit="6"/>
                  <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 366 (N=90,96,91,100)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="1" lower_limit="0.026" upper_limit="6"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="1" lower_limit="0.025" upper_limit="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
        <description>Safety was assessed as the number of subjects who reported any AEs, and at least possibly related AEs are collected from day 1 to day 43 following vaccination with adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
        <time_frame>Day 1 to Day 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on unsolicited safety set - All subjects in the exposed set with unsolicited AE data.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="97"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
            <description>Safety was assessed as the number of subjects who reported any AEs, and at least possibly related AEs are collected from day 1 to day 43 following vaccination with adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="31"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
        <description>The number of subjects reporting unsolicited adverse events after receiving adjuvanted and unadjuvanted formulations of H7N9c vaccine was reported. Safety was assessed as the number of subjects who reported SAEs, at least possibly related SAEs, new onset of chronic diseases (NOCDs), medically attended AEs, AEs of Special Interest (AESIs), AEs leading to withdrawal from the study were collected from day 1 to day 366 following vaccination with adjuvanted and unadjuvanted formulations of H7N9 vaccine.</description>
        <time_frame>Day 1 to Day 366.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on unsolicited safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Unsolicited Serious Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
            <description>The number of subjects reporting unsolicited adverse events after receiving adjuvanted and unadjuvanted formulations of H7N9c vaccine was reported. Safety was assessed as the number of subjects who reported SAEs, at least possibly related SAEs, new onset of chronic diseases (NOCDs), medically attended AEs, AEs of Special Interest (AESIs), AEs leading to withdrawal from the study were collected from day 1 to day 366 following vaccination with adjuvanted and unadjuvanted formulations of H7N9 vaccine.</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>At least possibly related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs leading to withdrawal</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Medically attended AE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="34"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AESI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>NOCD</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
        <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 to day 7 of vaccination of adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
        <time_frame>Day 1 through Day 7 after each vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was done on the solicited safety set - All subjects in the exposed set with solicited AE data.</population>
        <group_list>
          <group group_id="O1">
            <title>Low Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O3">
            <title>High Dose + Adj</title>
            <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
          <group group_id="O4">
            <title>High Dose + No Adj</title>
            <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="98"/>
                  <measurement group_id="O2" value="103"/>
                  <measurement group_id="O3" value="98"/>
                  <measurement group_id="O4" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Adjuvanted and Unadjuvanted Formulations of H7N9c Vaccine</title>
            <description>Safety was assessed as the number of subjects who reported solicited local and systemic adverse events from day 1 to day 7 of vaccination of adjuvanted and unadjuvanted formulations of H7N9c vaccine.</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any local-Vaccination I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="60"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="74"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any systemic-Vaccination I</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="56"/>
                  <measurement group_id="O3" value="44"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="23"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="10"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="32"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="11"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="23"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temp (≥38°C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of pain and/or fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of pain and/or fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Local-Vaccination II (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="58"/>
                  <measurement group_id="O3" value="46"/>
                  <measurement group_id="O4" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="53"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ecchymosis (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="6"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Systemic-Vaccination II (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="17"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="15"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Loss of appetite (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Body Temp (≥38°C; N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prevention of pain and/or fever (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Treatment of pain and (or)fever (N=95,102,97,102)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited and unsolicited AEs collected from Day 1 to Day 7; SAEs, NOCD, medically attended AEs, AEs leading to withdrawal, AESI and concomitant medications associated with these events are collected from day 1 through day 366.</time_frame>
      <desc>All Solicited AEs are classified as systematic assessment and all unsolicited AEs are classified as non-systematic assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="E2">
          <title>Medium Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="E3">
          <title>High Dose + Adj</title>
          <description>Subjects received two doses of MF59 adjuvanted H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="E4">
          <title>High Dose + No Adj</title>
          <description>Subjects received two doses of unadjuvanted of H7N9c vaccine formulation, administered three weeks apart.</description>
        </group>
        <group group_id="E5">
          <title>TOTAL</title>
          <description>Total of all reporting groups.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="299" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="124" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="234" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="96" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="48" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="71" subjects_at_risk="401"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="103"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="98"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="102"/>
                <counts group_id="E5" subjects_affected="137" subjects_at_risk="401"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
